PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.91%
Revenue growth 1.25-1.5x TSM's 13.86%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
-17.38%
Negative gross profit growth while TSM is at 17.52%. Joel Greenblatt would examine cost competitiveness or demand decline.
52.33%
EBIT growth above 1.5x TSM's 18.58%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
52.33%
Operating income growth above 1.5x TSM's 18.58%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
47.70%
Net income growth above 1.5x TSM's 19.66%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
48.39%
EPS growth above 1.5x TSM's 19.23%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
48.39%
Diluted EPS growth above 1.5x TSM's 19.23%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.80%
Share count expansion well above TSM's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.80%
Diluted share count expanding well above TSM's 0.00%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4.93%
Negative OCF growth while TSM is at 6.28%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-3.21%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
509.80%
10Y revenue/share CAGR above 1.5x TSM's 131.54%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
55.35%
5Y revenue/share CAGR at 50-75% of TSM's 87.97%. Martin Whitman would worry about a lagging mid-term growth trajectory.
8.55%
3Y revenue/share CAGR under 50% of TSM's 43.91%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
2607.97%
OCF/share CAGR of 2607.97% while TSM is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
526.71%
5Y OCF/share CAGR above 1.5x TSM's 85.03%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
663.79%
3Y OCF/share CAGR above 1.5x TSM's 45.42%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-1062.70%
Negative 10Y net income/share CAGR while TSM is at 126.83%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1976.89%
Negative 5Y net income/share CAGR while TSM is 139.53%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-216.66%
Negative 3Y CAGR while TSM is 62.36%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1568.61%
Equity/share CAGR of 1568.61% while TSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
87.24%
5Y equity/share CAGR above 1.5x TSM's 34.16%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
30.55%
3Y equity/share CAGR above 1.5x TSM's 7.47%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.63%
AR growth well above TSM's 21.61%. Michael Burry fears inflated revenue or higher default risk in the near future.
-14.68%
Inventory is declining while TSM stands at 9.28%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.77%
Asset growth well under 50% of TSM's 8.61%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-3.85%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.15%
We’re deleveraging while TSM stands at 152.81%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-36.10%
Our R&D shrinks while TSM invests at 12.17%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-37.77%
We cut SG&A while TSM invests at 16.98%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.